|Bid||25.74 x 1000|
|Ask||25.85 x 1200|
|Day's Range||24.59 - 26.20|
|52 Week Range||2.14 - 26.24|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 25, 2018 - Jul 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.36|
LONDON, UK / ACCESSWIRE / July 12, 2018 / If you want a free Stock Review on TRXC sign up now at www.wallstequities.com/registration. WallStEquities.com takes a close look at four Medical Instruments and Supplies stocks, particularly, Tandem Diabetes Care Inc. (NASDAQ: TNDM), The Cooper Cos. Inc. (NYSE: COO), TransEnterix Inc. (NYSE American: TRXC), and Waters Corp. (NYSE: WAT).
On June 26, Tandem Diabetes Care (TNDM) ended the trading day at $23.64, ~7.3% lower than its 52-week low of $25.50 reached on June 22, triggered by news of the FDA’s approval of the company’s new insulin pump. On June 26, Tandem stock was trading ~1,000% higher than the 52-week low of $2.14 it reached on February 9.
In fiscal 2018, Tandem Diabetes Care (TNDM) expects sales at the mid-to-upper end of its $132 million–$140 million guidance. This confident sales outlook comes despite the company discontinuing its t:flex insulin pump by the end of fiscal Q2 2018. The company registered sales of $102.6 million in fiscal 2017 and $27.3 million in Q1 2018, ahead of analysts’ estimates.
Tandem Diabetes Care Rises 21%: Could It See More Upside? Tandem Diabetes Care (TNDM) is slated to begin its international expansion later this year to capture opportunities arising after Johnson & Johnson’s (JNJ) exit from the insulin pump market, which was announced in October 2017. At the time, the move largely benefited Medtronic (MDT), the largest player in the insulin pump market.
After the market closed on June 21, Tandem Diabetes Care (TNDM) announced the FDA’s approval of its t:slim X2 insulin pump. Following the news, Oppenheimer analyst Steven Lichtman shared his views on Tandem, writing, “Approval timing is in line, though compatibility with Dexcom’s new G6 sensor in the initial approval is upside to expectations; TNDM had assumed a staggered approval with G5 compatibility first, potentially followed shortly thereafter by iCGM designation/G6 compatibility.” He added, “Earlier G6 approval bodes well for the initial launch later this summer. ...
Apart from selling insulin pumps, Tandem Diabetes Care (TNDM) also sells disposable products that are used together with pumps and are replaced every few days. These include cartridges and infusion sets. Tandem’s products on the market include t:slim, t:flex, and t:slim G4. In October 2016, Tandem commercialized t:slim X2 and discontinued t:slim. At present, the t:slim X2 platform represents almost the entire new pump shipments of the company. Tandem plans to discontinue sales of t:flex pumps from Q3 2018.
Tandem Diabetes Care’s (TNDM) t:slim X2 with control IQ is its second generation AID system that is expected to integrate the t:slim X2 pump with the technology Tandem licensed from TypeZero Technologies and Dexcom’s (DXCM) G6 sensor. In its international diabetes closed loop (or IDCL) trial, Tandem is working with TypeZero and Dexcom on the integration of their technologies. Further, Tandem plans to use these results in a premarket approval (or PMA) submission to the U.S. Food and Drug Administration (or FDA).
Due to the decrease in SG&A expenses, the total operating expenses of Tandem Diabetes Care decreased from $28.0 million in Q1 2017 to $26.9 million in Q1 2018, which further helped the company in reducing its operating loss to $15.5 million in Q1 2018 as compared with an operating loss of $21.2 million in Q1 2017.
|Initiated||Lake Street: to Buy||6/18/2018|
|Upgrade||PiperJaffray: Neutral to Overweight||5/14/2018|
|Upgrade||Cowen & Co.: Market Perform to Outperform||3/28/2018|
|Upgrade||Baird: Neutral to Outperform||3/23/2018|
|Initiated||Oppenheimer: to Outperform||2/27/2018|
|Downgrade||PiperJaffray: to Neutral||11/3/2016|
Industry: Medical Devices
Full Time Employees: 574
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:flex insulin delivery system that includes t:flex pump, its 480-unit disposable insulin cartridge, and an infusion set; t:slim X2 with G5 integration; and Tandem Device Updater, a PC and Mac-compatible tool that allows users to update their pump's software. In addition, the company offers t:connect diabetes management application, a cloud-based data management application, which provides a visual way to display therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers; t:lock cartridge and infusion set products; and various pump accessories. Its products in development include automated insulin delivery systems; t:slim X2 with Basal IQ; t:slim X2 with control IQ; t:sport insulin delivery system; and connected (mobile) health mobile application. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California.